Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Inactivated Influenza Vaccine Market Size And Revenue Outlook Through 2030
The inactivated influenza vaccine market size has shown significant expansion in recent years. Its valuation is projected to increase from $7.14 billion in 2025 to $7.72 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. The contributing factors to its historical development include a rise in seasonal influenza occurrences, the enlargement of immunization efforts, heightened understanding of preventive healthcare, the existence of egg-based vaccine production methods, and an increase in public health campaigns.
The inactivated influenza vaccine market is anticipated to experience substantial growth in the coming years. It is projected to expand to $10.55 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period is driven by an increasing emphasis on pandemic preparedness, rising investments in cell-based and recombinant vaccines, the broadening of adult and elderly immunization coverage, growing government procurement of vaccines, and advancements in vaccine manufacturing technologies. Significant trends influencing the forecast period include the increasing adoption of quadrivalent influenza vaccines, a rising focus on high-dose and adjuvanted vaccines, the expansion of seasonal vaccination programs, a growing emphasis on cold-chain optimization, and an enhanced focus on vaccine manufacturing scalability.
Get A Free Sample Report With In-Depth Market Insights:
Inactivated Influenza Vaccine Market Demand Drivers Opening New Revenue Streams
Growing government vaccination initiatives are anticipated to boost the inactivated influenza vaccine market’s expansion in the future. These programs are broadening due to increased public health consciousness among populations, generating greater demand for immunization services and prompting governments to improve vaccine availability and outreach efforts. Such programs aid the delivery of inactivated influenza vaccines by offering complimentary or reduced-cost access to vulnerable demographics, guaranteeing fair immunization coverage, and lessening the impact of seasonal influenza. As an illustration, in December 2023, the National Health Service, a UK-based government agency, launched an NHS vaccine strategy aimed at achieving immunization objectives. This strategy incorporates plans for community-focused vaccination services, specifically targeting neglected and disadvantaged populations. Consequently, the increase in government vaccination programs is fueling the growth of the inactivated influenza vaccine market.
Inactivated Influenza Vaccine Market Segment Breakdown: Which Categories Lead On Revenue?
The inactivated influenza vaccine market covered in this report is segmented –
1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV), Quadrivalent Inactivated Influenza Vaccine (QIIV)
2) By Application: Children, Adolescence, Adults, Elderly
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Clinics
4) By End-User: Healthcare Providers, Individuals, Government Organizations, Pharmaceutical Companies
Subsegments:
1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine, Cell-based Trivalent Inactivated Influenza Vaccine, Adjuvanted Trivalent Inactivated Influenza Vaccine, High-dose Trivalent Inactivated Influenza Vaccine
2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine, Cell-based Quadrivalent Inactivated Influenza Vaccine, Adjuvanted Quadrivalent Inactivated Influenza Vaccine, Recombinant Quadrivalent Inactivated Influenza Vaccine, Pediatric Quadrivalent Inactivated Influenza Vaccine
Inactivated Influenza Vaccine Market Trends Powering Strategic Industry Growth
Prominent companies operating within the inactivated influenza vaccine market are primarily focused on developing quadrivalent inactivated influenza vaccines to offer comprehensive protection against four different strains of the influenza virus. A quadrivalent inactivated influenza vaccine serves as a flu shot designed to protect against four distinct flu viruses. For instance, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, rolled out VaxiFlu-4, a quadrivalent inactivated influenza vaccine intended to provide seasonal defense against four new virus strains. VaxiFlu-4 delivers more extensive protection by covering both influenza A and B strains, thereby lowering the risk of vaccine mismatch. This vaccine seeks to manage seasonal flu outbreaks with an enhanced immune response aligned with regional epidemiological patterns.
Inactivated Influenza Vaccine Market Competitive Overview And Top Companies
Major companies operating in the inactivated influenza vaccine market are Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Viatris Inc., Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Hualan Biological Bacterin Co. Ltd., Changchun Biological Products Co. Ltd., Dalian Aleph Biomedical Co. Ltd., Jiangsu GDK Biotechnology Co. Ltd., KM Biologics Co. Ltd., JoinHub Pharma, Seqirus (CSL Influenza Division), Serum Institute of India Pvt. Ltd., Biological E. Limited, Shenzhen Sanofi Pasteur Biologicals Co. Ltd., Beijing Tiantan Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Sinopharm CNBG, Takeda Pharmaceutical Company Limited, Pfizer
View The Full Inactivated Influenza Vaccine Market Report:
Inactivated Influenza Vaccine Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the inactivated influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
